The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner.

D Vara, M Campanella, G Pula
Author Information
  1. D Vara: Department of Pharmacy and Pharmacology, University of Bath, Bath Spa, UK.

Abstract

BACKGROUND AND PURPOSE: NADPH oxidases (NOXs) contribute to platelet activation by a largely unknown mechanism. Here, we studied the effect of the novel NOX inhibitor 2-acetylphenothiazine (2-APT) on human platelet functional responses and intracellular signaling pathways.
EXPERIMENTAL APPROACH: The generation of superoxide ions was assessed by single cell imaging on adhering platelets using dihydroethidium (DHE), while other reactive oxygen species (ROS) were detected with 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate (CM-H(2)-DCFDA). Whole blood thrombus formation, washed platelet aggregation, integrin αIIbβ3 inside-out signalling, Syk phosphorylation and PKC activation were analysed to understand the functional consequences of NOX inhibition by 2-APT in platelets.
KEY RESULTS: Superoxide ion generation stimulated by platelet adhesion on collagen and fibrinogen was significantly inhibited by 2-APT in concentration-dependent manner (IC(50) = 306 nM and 227 nM, respectively), whereas cumulative ROS accumulation was not affected by this pharmacological agent. 2-APT also abolished collagen-dependent whole blood thrombus formation and washed platelet aggregation in response to collagen but not thrombin. The activation of integrin αIIbβ3 and PKC in response to the GPVI-specific agonist collagen-related peptide (CRP) was significantly reduced, whereas the same responses to thrombin were not significantly affected by 2-APT. Finally, Syk activation in response to collagen but not thrombin was inhibited by 2-APT.
CONCLUSIONS AND IMPLICATIONS: Taken together, our results suggest that 2-APT attenuates GPVI-specific signalling and is a novel inhibitor of collagen-induced platelet responses. Therefore, NOXs could represent a novel target for the discovery of anti-thrombotic drugs.

References

  1. J Mol Med (Berl). 2011 Feb;89(2):109-21 [PMID: 21058007]
  2. Hypertension. 2008 Feb;51(2):211-7 [PMID: 18086956]
  3. Lab Chip. 2008 Sep;8(9):1486-95 [PMID: 18818803]
  4. Blood. 2002 Aug 1;100(3):917-24 [PMID: 12130503]
  5. Blood. 2005 Oct 15;106(8):2757-60 [PMID: 15976180]
  6. Cell. 1996 Jan 26;84(2):289-97 [PMID: 8565074]
  7. Free Radic Biol Med. 2007 Jul 1;43(1):22-30 [PMID: 17561090]
  8. J Biol Chem. 2007 Oct 19;282(42):30434-41 [PMID: 17690106]
  9. Free Radic Biol Med. 2008 Jul 15;45(2):158-66 [PMID: 18452718]
  10. J Thromb Haemost. 2010 Mar;8(3):454-62 [PMID: 20002545]
  11. Thromb Haemost. 2000 Mar;83(3):485-90 [PMID: 10744158]
  12. J Biol Chem. 2005 Feb 25;280(8):7194-205 [PMID: 15583006]
  13. FASEB J. 2000 Dec;14(15):2377-9 [PMID: 11024007]
  14. J Clin Invest. 2009 Feb;119(2):399-407 [PMID: 19147982]
  15. J Pharmacol Exp Ther. 2012 Apr;341(1):156-63 [PMID: 22238212]
  16. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s5-10 [PMID: 18174454]
  17. FASEB J. 2006 Jun;20(8):1082-9 [PMID: 16770007]
  18. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s11-6 [PMID: 18174453]
  19. Blood. 2008 Sep 1;112(5):1696-703 [PMID: 18544684]
  20. Naunyn Schmiedebergs Arch Pharmacol. 2010 Oct;382(4):377-84 [PMID: 20809239]
  21. Trends Pharmacol Sci. 2003 Sep;24(9):471-8 [PMID: 12967772]
  22. Nat Protoc. 2008;3(6):941-7 [PMID: 18536642]
  23. Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15038-43 [PMID: 17015830]
  24. J Biol Chem. 2006 Sep 8;281(36):26665-74 [PMID: 16837456]
  25. Circulation. 2007 May 1;115(17):2323-30 [PMID: 17438148]
  26. Blood. 2003 Sep 15;102(6):2085-92 [PMID: 12791669]
  27. J Thromb Haemost. 2011 Mar;9(3):608-10 [PMID: 21251194]
  28. Blood Cells Mol Dis. 2006 Mar-Apr;36(2):166-70 [PMID: 16469512]
  29. J Thromb Haemost. 2011 Jul;9 Suppl 1:92-104 [PMID: 21781245]
  30. J Clin Invest. 1977 May;59(5):959-65 [PMID: 192766]
  31. Circulation. 1997 Feb 18;95(4):885-91 [PMID: 9054746]
  32. Platelets. 2008 May;19(3):199-210 [PMID: 18432521]
  33. Antioxid Redox Signal. 2004 Aug;6(4):691-8 [PMID: 15242549]
  34. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):1988-96 [PMID: 15374851]
  35. Thromb Res. 2001 Sep 1;103(5):399-409 [PMID: 11553372]
  36. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):187-92 [PMID: 14604832]
  37. Platelets. 2002 May;13(3):175-82 [PMID: 12180500]
  38. Free Radic Biol Med. 1997;22(6):999-1006 [PMID: 9034239]
  39. Pharmacol Rep. 2008 Jan-Feb;60(1):21-8 [PMID: 18276982]
  40. Front Biosci. 2008 May 01;13:3532-48 [PMID: 18508453]
  41. Blood. 2006 Dec 15;108(13):4035-44 [PMID: 16940418]
  42. Nat Rev Drug Discov. 2011 Jun;10(6):453-71 [PMID: 21629295]
  43. Platelets. 2008 Feb;19(1):1-8 [PMID: 18231933]
  44. Atherosclerosis. 2004 Sep;176(1):95-9 [PMID: 15306180]
  45. Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1698-706 [PMID: 9812907]
  46. Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2631-8 [PMID: 20884872]
  47. ACS Chem Biol. 2010 Oct 15;5(10):981-93 [PMID: 20715845]
  48. Circulation. 2004 Sep 7;110(10):1326-9 [PMID: 15249506]

Grants

  1. /United Kingdom

MeSH Term

Collagen
Fibrinolytic Agents
Humans
In Vitro Techniques
Membrane Glycoproteins
NADPH Oxidase 1
NADPH Oxidase 2
NADPH Oxidases
Phenothiazines
Platelet Activation
Platelet Adhesiveness
Platelet Aggregation
Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Membrane Glycoproteins
Signal Transduction
Thrombosis

Chemicals

2-acetylphenothiazine
Fibrinolytic Agents
Membrane Glycoproteins
Phenothiazines
Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Membrane Glycoproteins
Collagen
CYBB protein, human
NADPH Oxidase 1
NADPH Oxidase 2
NADPH Oxidases
NOX1 protein, human

Word Cloud

Created with Highcharts 10.0.02-APTplateletactivationnovelNOXinhibitorresponsesthrombusformationcollagensignificantlyresponsethrombinANDNOXs2-acetylphenothiazinefunctionalgenerationplateletsROSbloodwashedaggregationintegrinαIIbβ3signallingSykPKCinhibitedmannernMwhereasaffectedcollagen-dependentGPVI-specificBACKGROUNDPURPOSE:NADPHoxidasescontributelargelyunknownmechanismstudiedeffecthumanintracellularsignalingpathwaysEXPERIMENTALAPPROACH:superoxideionsassessedsinglecellimagingadheringusingdihydroethidiumDHEreactiveoxygenspeciesdetected5-and-6-carboxy-2'7'-dichlorodihydrofluoresceindiacetateCM-H2-DCFDAWholeinside-outphosphorylationanalysedunderstandconsequencesinhibitionKEYRESULTS:Superoxideionstimulatedadhesionfibrinogenconcentration-dependentIC50=306227respectivelycumulativeaccumulationpharmacologicalagentalsoabolishedwholeagonistcollagen-relatedpeptideCRPreducedFinallyCONCLUSIONSIMPLICATIONS:Takentogetherresultssuggestattenuatescollagen-inducedThereforerepresenttargetdiscoveryanti-thromboticdrugsimpairsGPVI-dependent

Similar Articles

Cited By